THE MEDICAL COLLEGE OF WISCONSIN, INC.

Real-world data from 877 patients and clinical trial data from 702 patients demonstrate that most cytokine release syndrome and neurological events with lisocabtagene maraleucel occur within 15 days of infusion and are not severe.

Kite presented real-world data from 238 patients showing comparable safety and effectiveness outcomes for Yescarta CAR-T therapy administered in outpatient versus inpatient settings for relapsed/refractory large B-cell lymphoma.

Leading experts at the 2025 Transplant and Cellular Therapy Meetings emphasize the critical need to address social vulnerabilities affecting patient access to stem cell transplants and CAR T-cell therapies.

Phase 2 ACCESS trial demonstrates 84% one-year overall survival rate using post-transplant cyclophosphamide for GVHD prevention in HLA-mismatched unrelated donor transplants.

Dana-Farber researchers will showcase novel findings on multiple myeloma treatment outcomes based on Duffy genotype at the 2025 Tandem Meetings, revealing significant implications for personalized therapy selection.

Omeros Corporation will present real-world data from 128 transplant patients treated with narsoplimab for TA-TMA under an expanded access program at the 2025 Tandem Meetings in Honolulu.

Children from high-poverty neighborhoods face 25% transplant-related mortality compared to 20% in low-poverty areas, with Black children experiencing 65% higher risk of transplant-related mortality.